Nuveen Asset Management LLC Has $41.96 Million Position in Repligen Co. (NASDAQ:RGEN)

Nuveen Asset Management LLC reduced its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 13.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 291,537 shares of the biotechnology company's stock after selling 43,567 shares during the quarter. Nuveen Asset Management LLC owned about 0.52% of Repligen worth $41,964,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ballentine Partners LLC raised its stake in Repligen by 4.0% during the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock valued at $270,000 after buying an additional 72 shares during the last quarter. CIBC Asset Management Inc raised its stake in shares of Repligen by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock worth $246,000 after purchasing an additional 81 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Repligen by 0.7% in the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock worth $2,087,000 after purchasing an additional 100 shares during the last quarter. Utah Retirement Systems raised its stake in shares of Repligen by 1.1% in the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock worth $1,338,000 after purchasing an additional 100 shares during the last quarter. Finally, Peapack Gladstone Financial Corp raised its stake in shares of Repligen by 5.2% in the fourth quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company's stock worth $301,000 after purchasing an additional 103 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Insider Activity

In other Repligen news, Director Margaret Pax purchased 250 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.20% of the company's stock.

Repligen Price Performance

Shares of RGEN stock traded down $2.30 during midday trading on Friday, reaching $118.15. 615,767 shares of the company traded hands, compared to its average volume of 740,875. The firm's 50 day simple moving average is $130.28 and its two-hundred day simple moving average is $144.49. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a market cap of $6.64 billion, a PE ratio of -231.67, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. During the same period last year, the firm earned $0.28 EPS. The company's revenue for the quarter was up 10.4% on a year-over-year basis. On average, equities research analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on RGEN shares. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a research note on Tuesday, April 29th. JPMorgan Chase & Co. decreased their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Canaccord Genuity Group cut their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. TD Cowen started coverage on Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective for the company. Finally, Wall Street Zen raised Repligen from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $173.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.